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Abstract 
Background 
Different diagnostic criteria limit comparisons between populations in the prevalence of 
diastolic left ventricular (LV) dysfunction. We aimed to compare across populations age-
specific echocardiographic criteria for diastolic LV dysfunction as well as their correlates and 
prevalence. 
Methods 
We measured the E and A peaks of transmitral blood flow by pulsed wave Doppler and the e’ 
and a’ peaks of mitral annular velocities by tissue Doppler imaging (TDI) in 2 cohorts 
randomly recruited in Belgium (n = 782; 51.4% women; mean age, 51.1 years) and in Italy, 
Poland and Russia (n = 476; 55.7%; 44.5 years). 
Results 
In stepwise regression, the multivariable-adjusted correlates of the transmitral and TDI 
diastolic indexes were similar in the 2 cohorts and included sex, age, body mass index, blood 
pressure and heart rate. Similarly, cut-off limits for the E/A ratio (2.5th percentile) and E/e’ 
ratio (97.5th percentile) in 338 and 185 reference subjects free from cardiovascular risk 
factors respectively selected from both cohorts were consistent within 0.02 and 0.26 units 
(median across 5 age groups). The rounded 2.5th percentile of the E/A ratio decreased by 
~0.10 per age decade in these apparently healthy subjects. The reference subsample provided 
age-specific cut-off limits for normal E/A and E/e’ ratios. In the 2 cohorts combined, diastolic 
dysfunction groups 1 (impaired relaxation), 2 (possible elevated LV filling pressure) and 3 
(elevated E/e’ and abnormally low E/A) encompassed 114 (9.1%), 135 (10.7%), and 40 
(3.2%) subjects, respectively. 
Conclusions 
The age-specific criteria for diastolic LV dysfunction were highly consistent across the study 
populations with an age-standardized prevalence of 22.4% vs. 25.1%. 
Keywords 
Epidemiology, Echocardiography, Tissue Doppler Imaging, Diastole 
MK-B and TK contributed equally to this work. 
Background 
Cardiovascular risk factors underlie the first stage of diastolic heart failure (HF). This stage 
evolves into asymptomatic left ventricular diastolic dysfunction (LVDD) characterized by 
impaired relaxation and increased left ventricular (LV) stiffness, and finally progresses to 
clinically overt diastolic HF. [1] Recently published community-based studies making use of 
conventional and tissue Doppler echocardiographic imaging (TDI) revealed a high prevalence 
of LVDD, ranging from 11.1% up to 34.7%. [2-8] In the Flemish Study on Environment, 
Genes and Health Outcomes (FLEMENGHO), the frequency was 27.3%. [9] One issue 
making the interpretation of the aforementioned reports difficult is that the prevalence of 
LVDD cannot be easily compared, partially because of differing diagnostic criteria and/or 
divergent distributions of cardiovascular risk factors in the sampled populations (for review 
see Additional file 1: Tables S1 and S2). In the FLEMENGHO study, [9] we derived age-
specific criteria for the classification of LVDD based on a reference sample. Since the 
publication of our previous report, [9] echocardiographic examinations continued in the 
FLEMENGHO cohort and started in four centers taking part in the European Project on 
Genes in Hypertension (EPOGH). In the present study, we compared age-specific 
echocardiographic criteria for LVDD across populations as well as the correlates and 
prevalence of this condition. By showing consistency across populations, we aimed to 
propose a diagnostic classification that might be useful in clinical practice. 
Methods 
Study participants 
From August 1985 until December 2005, we randomly recruited a family-based population 
sample from a geographically defined area in northern Belgium as described elsewhere. [9] 
EPOGH recruited participants from 1999 until 2001. The EPOGH investigators were trained 
at the Studies Coordinating Centre, and applied the same protocol, questionnaires and follow-
up procedures, as used in FLEMENGHO. The FLEMENGHO and EPOGH studies received 
ethical approval. The initial response rate at enrolment was 61.3%. [10,11] All subjects 
provided informed consent in writing. 
The FLEMENGHO and EPOGH participants remained in follow-up. Five centers opted to 
perform echocardiographic phenotyping and to assess LV function by using the new TDI 
indexes along with classical pulsed wave Doppler velocities of blood flow. Our current study 
population includes 1287 subjects, who were examined from June 2005 until September 
2009. We excluded 29 subjects from analysis, because of atrial fibrillation (n = 12), a 
pacemaker (n = 2), or because LVDD could not be reliably determined (n = 15). Thus, the 
current analysis included 1258 participants: 782 FLEMENGHO participants 
(Noorderkempen, Belgium) and 476 EPOGH subjects from Gdańsk (n = 108) and Kraków 
(n = 124), Poland, Mirano, Italy (n = 106), and Novosibirsk, Russia (n = 138). 
Echocardiography 
In each center one experienced physician did the ultrasound examination, using a Vivid 7 Pro 
(GE Vingmed, Horten, Norway), interfaced with a 2.5- to 3.5-MHz phased-array probe, 
according to a standardized protocol described in detail in previous publications. [9] With the 
subjects in partial left decubitus and breathing normally, the observer obtained images, 
together with a simultaneous ECG signal, along the parasternal long and short axes and from 
the apical 4-, 2-chamber and long-axis views. All recordings included at least 5 cardiac cycles 
and were digitally stored for off-line analysis. 
One experienced observer (TK) analyzed the digitally stored images, using the EchoPac 
software, version 4.0.4 (GE Vingmed), averaging three cardiac cycles. The LV internal 
diameter and interventricular septal and posterior wall thickness were measured at end-
diastole from the 2-dimensionally guided M-mode tracings according to the 
recommendations. [12] When optimal orientation of M-mode ultrasound beam could not be 
obtained, the reader performed linear measurements on correctly oriented two-dimensional 
images. End-diastolic LV dimensions were used to calculate LV mass by an anatomically 
validated formula. LV hypertrophy was a left ventricular mass index (LVMI) of 125 g/m2 in 
men and 110 g/m2 in women or more. We calculated LV ejection fraction (EF) from LV end-
systolic and end-diastolic volumes measured from the apical 4- and 2-chambers views, using 
the standard biplane Simpson’s method. We measured left atrial (LA) dimensions in 3 
orthogonal planes: the parasternal long, lateral, and supero-inferior axes. [13] LA volume 
(LAVI) was calculated using the prolate-elipsoid method [13] and was indexed to body 
surface area. 
From the transmitral flow signal, we measured peak early (E) and late (A) diastolic velocities, 
the E/A ratio and A flow duration. The duration of PV reversal flow during atrial systole 
(AR) was measured from the PV flow signal. From the pulsed wave TDI recordings, we 
measured the early (e’) and late (a’) peak diastolic velocities of the mitral annulus 
displacement, and the e’/a’ ratio at the 4 acquisition sites (septal, lateral, inferior, and 
posterior). We calculated the E/e’ ratio by dividing transmitral E peak by e’ averaged from 
the 4 acquisition sites. As reported previously, [9] the inter-observer intra-session 
reproducibility across the four sampling sites ranged from 4.48% to 5.34% for e’ velocities 
and from 3.96% to 4.52% for a’ velocities. 
Other measurements 
We administered a standardized questionnaire to collect detailed information on each 
subject’s medical history, smoking and drinking habits, and intake of medications. The 
conventional blood pressure was the average of five consecutive auscultatory readings 
obtained with the subject in the seated position. Hypertension was a blood pressure of at least 
140 mmHg systolic or 90 mmHg diastolic or the use of antihypertensive drugs. Body mass 
index (BMI) was weight in kilograms divided by the square of height in meters. Obesity was 
a BMI of 30 kg/m² or higher. Central obesity was a waist circumference of at least 102 cm in 
men or 88 cm in women. Diabetes was a fasting blood glucose of 7.0 mmol/L or higher or the 
use of antidiabetic agents. 
NT-proBNP in the FLEMENGHO study was measured in plasma by a competitive enzymatic 
immunoassay for research use (Biomedica Gruppe, Vienna, Austria). [14] NT-proBNP in the 
EPOGH study was determined in serum by an electrochemiluminescence immunoassay 
Elecsys 2010 (Roche Diagnostics, Indianapolis, USA). [14] 
To generate a reference sample, we excluded participants, if one or more of the following 
conditions were present: hypertension (FLEMENGHO/EPOGH, n = 323/211), diabetes 
(n = 29/25), obesity (n = 143/134), central obesity (n = 216/144), LV hypertrophy (n = 84/36), 
renal failure (n = 4/4) or cardiac diseases (valvular abnormalities, n = 31/8; myocardial 
infarction and/or coronary revascularization, n = 24/6). The number of subjects in the 
reference group was 338 in FLEMENGHO, 185 in EPOGH, and 523 in total. 
Statistical methods 
For database management and statistical analysis, we used SAS software, version 9.1.3 (SAS 
Institute, Cary, NC). We compared means and proportions by means of a large sample z-test 
and the χ2-test, respectively. We performed single and stepwise linear regression to identify 
correlates of the Doppler indexes as measured on a continuous scale. We set the P-values for 
variables to enter and to stay in the regression models at 0.05. To obtain 95% confidence 
intervals of the percentile values of the E/A distributions, we computed the bootstrap 
distribution [15] of the thresholds by randomly resampling the study population 1000 times 
with replacement, using the PROC SURVEYSELECT procedure, as implemented in the SAS 
software. Because NT-proBNP was measured by different methods in FLEMENGHO and 
EPOGH, we rescaled the values by computing population-specific z-scores, which reflect the 
deviation of each individual measurement from the population mean. 
Results and discussion 
Characteristics of participants 
The 1258 participants included 666 (52.9%) women, and 534 (42.5%) hypertensive patients 
of whom 325 (26.0%) were on antihypertensive drug treatment. Mean age (±SD) was 
48.5 ± 15.7 years. Tables 1 and 2 list the clinical and echocardiographic characteristics of the 
FLEMENGHO and EPOGH participants in the entire study population and in the reference 
groups. The participants were older in FLEMENGHO than in EPOGH. LAVI, LV wall 
thickness, LVMI and EF (Table 2) were greater in FLEMENGHO than in EPOGH 
participants. Only 11 subjects (0.9%) had an EF less than 50%. The FLEMENGHO 
participants also had lower E/A and e’/a’ ratios (Table 2). Additional file 1: Tables S3 and S4 
show the clinical and echocardiographic characteristics of the EPOGH participants by center. 
Table 1  Characteristics of participants 
 Entire population Reference group 
Characteristic FLEMENGHO EPOGH FLEMENGHO EPOGH 
 (n = 782) (n = 476) (n = 338) (n = 185) 
Anthropometrics 
Women, n (%) 402 (51.4) 265 (55.7) 172 (50.9) 110 (59.8) 
Age, y 51.1±15.4 44.5 ± 15.1‡ 42.5±13.1 34.6 ± 11.7‡ 
Height, cm 168.7 ± 9.46 168.0 ± 9.0 170.4 ± 9.1 168.7 ± 8.76* 
Weight, kg 75.4 ± 14.4 76.3 ± 16.4 69.7 ± 11.4 66.1 ± 11.8‡ 
Body mass index, kg/m2 26.5 ± 4.31 27.0 ± 5.21 24.0 ± 2.76 23.1 ± 3.2† 
Waist circumference, cm 89.9 ± 12.3 89.6 ± 14.1 82.5 ± 9.24 79.2 ± 9.9‡ 
Systolic pressure, mm Hg 129.5 ± 17.6 130.5±19.9 118.3 ± 9.5 117.1 ± 11.5 
Diastolic pressure, mm Hg 79.6 ± 9.46 81.3±12.4* 75.2 ± 7.32 74.1 ± 7.9 
Heart rate, beats/minute 60.8 ± 9.63 67.0 ± 10.6‡ 60.3 ± 8.8 66.3 ± 9.5‡ 
Questionnaire data 
Current smoking, n (%) 167 (21.4) 102 (21.9) 98 (29.0) 40 (21.9) 
Drinking alcohol, n (%) 312 (39.9) 144 (30.2)‡ 157 (46.4) 43 (23.2)‡ 
Hypertensive, n (%) 323 (41.3) 211 (44.3) … … 
Treated for hypertension, n (%) 198 (25.32) 127 (27.2) … … 
Diabetes, n (%) 29 (3.71) 25 (5.25) … … 
Values are mean (±SD), or number of subjects (%). *P ≤0.05; †P ≤0.01; ‡P ≤0.001 
Table 2  Echocardiographic characteristics of participants 
 Entire population Reference group 
Characteristics FLEMENGHO EPOGH FLEMENGHO EPOGH 
 (n = 782) (n = 476) (n = 338) (n = 185) 
Conventional echocardiography 
Left atrium volume index, ml/m2 22.9±6.3 21.0 ± 5.6‡ 20.0±4.3 18.2 ± 3.8‡ 
LV internal diameter, cm 5.04±0.49 5.00 ± 0.43 4.99±0.43 4.88 ± 0.40† 
Interventricular septum, cm 0.98 ± 0.17 0.95 ± 0.16‡ 0.90±0.13 0.85 ± 0.12‡ 
Posterior wall, cm 0.89 ± 0.14 0.87 ± 0.13* 0.82±0.12 0.79 ± 0.11* 
LV mass index, g/m2 92.5 ± 21.9 87.9 ± 20.4‡ 82.9±15.4 77.9 ± 15.5‡ 
Ejection fraction,% 68.2 ± 7.4 62.6±5.9‡ 67.1±6.3 61.3 ± 5.5‡ 
Doppler data 
E peak, cm/s 75.4±15.9 71.6 ± 15.3‡ 79.7±14.7 76.1 ± 14.6† 
A peak, cm/s 65.0±17.5 58.6 ± 16.8‡ 55.6±12.8 48.4 ± 11.6‡ 
E/A ratio 1.26±0.48 1.33 ± 0.52† 1.52±0.49 1.66 ± 0.50† 
e’ peak#, cm/s 11.4±3.6 11.2 ± 3.6 13.8±3.1 13.7 ± 2.6 
a’ peak#, cm/s 10.1±2.1 9.23 ± 2.1‡ 9.37±2.1 8.19 ± 2.0‡ 
e’/a’ ratio# 1.24±0.64 1.36 ± 0.70† 1.63±0.68 1.84 ± 0.66‡ 
E/e’ ratio 7.08±2.2 6.88 ± 2.2 5.93±1.2 5.65 ± 1.1† 
Values are mean (±SD). # Averaged of septum, lateral, inferior and posterior mitral annulus 
sites. * P ≤0.05; †P≤0.01; ‡P ≤0.001. 
Determinants of transmitral and TDI velocity ratios 
In FLEMENGHO and EPOGH subjects, the E/A and e’/a’ ratios significantly and 
independently decreased with age, BMI, heart rate and diastolic blood pressure (Table 3). 
Furthermore, the e’/a’ ratio decreased with higher LVMI in the EPOGH participants. In both 
cohorts, the transmitral and mitral annular velocities ratios increased with systolic blood 
pressure. The E/e’ ratio increased with female sex, age, BMI, systolic blood pressure, and 
LVMI (Table 3). The E/e’ ratio decreased with higher diastolic blood pressure and LV length 
in both studies and with heart rate in FLEMENGHO participants. There were no differences 
in the partial regression coefficients between both studies (P ≥ 0.10). 
Table 3  Correlates of the E/A, e’/a’ and E/e’ ratios in stepwise regression by cohort 
Parameter Transmitral E/A Averaged TDI e’/a’ E/e’ 
 FLEMENG
HO 
EPOGH FLEMENG
HO 
EPOGH FLEMENG
HO 
EPOGH 
R2 (%) 67.5 65.9 73.6 71.2 49.6 46.2 
Adjusted 
R2 (%) 
67.3 65.4 73.4 70.6 49.0 45.1 
Partial regression coefficients 
Female 
(0,1) 
      
ß ± SE   0.064±0.025
* 
0.084±0.039
* 
0.62±0.15‡ 0.37±0.19* 
Partial r2 
(%) 
  0.22 0.29 1.4 0.44 
Age 
(+10 years
) 
      
ß ± SE −0.23±0.008
‡ 
−0.24±0.012
‡ 
−0.32±0.009
‡ 
−0.28±0.015
‡ 
0.38±0.048‡ 0.50±0.068
‡ 
Partial r2 
(%) 
53.6 51.4 61.1 54.4 33.6 35.4 
BMI 
(+1 kg/m2) 
      
ß ± SE −0.017±0.00
3‡ 
−0.011±0.00
3‡ 
−0.031±0.00
3‡ 
−0.026±0.00
4‡ 
0.093±0.015
‡ 
0.078±0.01
7‡ 
Partial r2 
(%) 
2.5 0.78 6.8 6.5 3.1 2.3 
HR (+10 
beats/minu
te) 
      
ß ± SE −0.13±0.011
‡ 
−0.13±0.014
‡ 
−0.11±0.013
‡ 
−0.13±0.017
‡ 
−0.16±0.063
† 
 
Partial r2 
(%) 
9.5 8.6 3.2 4.1 0.46  
SBP 
(+10 mmH
g) 
      
ß ± SE 0.025±0.008
† 
0.030±0.012
* 
0.044±0.010
‡ 
 0.36±0.045‡ 0.36±0.068
‡ 
Partial r2 
(%) 
0.43 0.43 0.7  5.1 4.2 
DBP (+ 
10 mmHg) 
      
ß ± SE −0.075±0.01
3‡ 
−0.079±0.01
9‡ 
−0.12±0.016
‡ 
−0.071±0.01
7‡ 
−0.21±0.076
† 
−0.27±0.10
† 
Partial r2 
(%) 
0.97 1.5 1.7 1.7 0.70 0.82 
LVMI 
(+10 g/m2) 
      
ß ± SE    −0.025±0.01
1* 
0.16±0.032‡ 0.13±0.049
† 
Partial r2 
(%) 
   0.67 1.4 0.49 
LV length 
(+1 cm) 
      
ß ± SE     −0.53±0.10‡ −0.45±0.13
‡ 
Partial r2 
(%) 
    3.8 1.8 
Values are mutually adjusted partial regression coefficients ± SE. BMI, body mass index; HR, 
heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVMI, left ventricle 
mass index. Significance of the partial regression coefficient: * P < 0.05, †P < 0.01, and 
‡P < 0.001. There were no differences between the partial regression coefficients in two 
studies (P ≥ 0.10) 
Transmitral and TDI Doppler indexes in the reference groups 
Additional file 1: Tables S5, S6 and S7 show the age-specific percentiles of the E/A, e’/a’ and 
E/e’ ratios, and LAVI in reference participants free from any cardiovascular disease or risk 
factors selected from the entire study population, FLEMENGHO and EPOGH, respectively. 
There was a significant decline in the E/A and e’/a’ ratio with age even in the reference group 
(P < 0.0001), because of significant decreases in E and e’ velocities and increases in A and a’ 
velocities (Additional file 1: Table S8). In the reference group (Additional file 1: Table S5), 
the E/e’ ratio increased with age (P < 0.0001). However, the 97.5 percentile of the E/e’ ratio 
in the entire reference group (8.60) approximated to the 8.5 cut-off limit for the normal filling 
pressure as observed in invasive studies. [16] In the 523 participants from the reference 
group, the 97.5 percentile of LAVI was 28.3 ml/m2. 
Table 4 shows the 2.5 and 97.5 age-group specific percentiles for the transmitral E/A ratio 
and the 97.5 percentiles for E/e’ in all reference subjects and in the FLEMEMGHO and 
EPOGH reference groups. Using the bootstrap approach, we calculated the confidence 
intervals of the 2.5 or 97.5 percentiles in the combined reference group by age categories. 
Next, we rounded these 2.5 and 97.5 age-specific percentiles to the closest integer value. All 
of these rounded thresholds fell within the 95% confidence boundaries for the 2.5 and 97.5 
age-specific percentiles of the E/A ratio and the 97.5 percentiles of the E/e’ ratio in the 
reference group (Table 4). 
Table 4  Age-specific percentiles for the E/A and E/e’ ratio in the reference groups 
Age group 
(years) 
FLEMENGHO 
(n = 338) 
EPOGH 
(n = 185) 
All subjects* 
(n = 523) 
95% CI for the 
age-specific 
percentiles 
Rounded 
limits 
Transmitral 
E/A 
2.5 percentile   
<30 1.23 1.23 1.23 1.17 to 1.31 1.20 
30–39 1.15 0.98 1.04 0.98 to 1.15 1.00 
40–49 0.88 0.95 0.91 0.87 to 0.95 0.90 
50–59 0.76 0.78 0.78 0.75 to 0.84 0.80 
≥60 0.67 0.67 0.67 0.66 to 0.74 0.70 
 97.5 percentile   
<30 3.22 3.25 3.18 2.87 to 3.25 3.20 
30–39 2.82 2.55 2.62 2.39 to 2.93 2.60 
40–49 2.36 2.05 2.22 2.04 to 2.51 2.20 
50–59 1.61 1.72 1.63 1.55 to 1.72 1.60 
≥60 1.55 1.28 1.48 1.28 to 1.55 1.50 
E/e’ 97.5 percentile   
<30 7.66 7.80 7.66 6.98 to 8.17 8.00 
30–39 7.47 8.24 7.47 7.04 to 8.56 8.00 
40–49 8.85 8.15 8.52 7.64 to 8.85 8.50 
50–59 8.84 8.83 8.84 8.60 to 9.62 9.00 
≥60 8.99 8.73 8.99 8.73 to 9.00 9.00 
* The average of the 2.5 and 97.5 percentiles obtained in the FLEMENGHO and EPOGH 
cohorts 
Prevalence of LVDD 
We combined the mitral inflow and TDI velocities to classify the stages of LVDD. The first 
group included subjects with an abnormally low age-specific transmitral E/A ratio indicative 
of impaired relaxation (less than rounded 2.5 percentile; Table 4), but without evidence of 
increased LV filling pressures (E/e’ ≤ 8.5). The second group had mildly-to-moderately 
elevated LV filling pressure (E/e’ > 8.5), and E/A ratio within the normal age-specific range 
(the rounded 2.5 to 97.5 percentile; Table 4). We used the differences in durations between 
the mitral A flow and the reverse PV flow during atrial systole (Ad < ARd + 10) and/or LAVI 
(≥ 28 ml/m2) to confirm possible elevation of the LV filling pressures in group 2. Group 3 
had combined LVDD with an elevated E/e’ ratio and an abnormally low age-specific E/A 
ratio. LVDD groups 1, 2 and 3 included 114 (9.1%), 135 (10.7%), and 40 (3.2%) subjects, 
respectively. Table 5 presents the prevalence of LVDD by study population, center, and age 
group respectively. With standardization to mean age, there were no differences in the 
prevalence of LVDD between the FLEMENGHO and EPOGH cohorts (22.4% vs. 25.1%; 
P = 0.09). However, in the EPOGH participants, the age-standardized prevalence of LVDD 
was lower (P < 0.04) in Italian participants (19.6%) than in the participants from Kraków 
(25.3%) and Novosibirsk (32.4%). The clinical and echocardiographic characteristics of the 
subjects by LVDD group appear in Additional file 1: Tables S9 and S10, respectively. 
Table 5  Diastolic function grades by study, center and age group 
 Diastolic function 
 Normal 
function 
1 group Impaired 
relaxation 
2 group Elevated LV 
filling pressure 
3 group Combined 
dysfunction 
Study 
FLEMENGHO 589 (75.3) 73 (9.3) 93 (11.9) 27 (3.5) 
EPOGH 380 (79.8) 41 (8.6) 42 (8.8) 13 (2.8) 
Center     
Gdańsk 94 (87.0) 7 (6.5) 6 (5.6) 1 (0.9) 
Kraków 103 (83.1) 8 (6.4) 10 (8.1) 3 (2.4) 
Mirano 85 (80.2) 9 (8.5) 8 (7.5) 4 (3.8) 
Novosibirsk 97 (70.4) 18 (13.0) 18 (13.0) 5 (3.6) 
Age group 
< 30 183 (96.3) 7 (3.7) ― ― 
30–39 197 (94.3) 10 (4.8) 2 (0.9) ― 
40–49 206 (91.2) 13 (5.7) 4 (1.8) 3 (1.3) 
50–59 240 (74.5) 39 (12.1) 34 (10.6) 9 (2.8) 
≥60 142 (45.7) 45 (14.5) 96 (30.8) 28 (9.0) 
Values are number (%). Impaired relaxation (group 1) indicates low E/A and normal E/e’; 
possible elevated LV filling pressure (group 2) indicates normal E/A and high E/e’; combined 
dysfunction (group 3) indicates low E/A and high E/e’ 
NT-proBNP and LV diastolic dysfunction 
Figure 1 shows histograms of the logarithmically transformed NT-proBNP levels and the 
corresponding z-scores by cohort. Compared to the participants with normal diastolic 
function (n = 969, 77.0%), subjects with elevated LV filling pressure (group 2) had 
significantly higher NT-proBNP (z-scores, –0.10 ± 0.94 vs. 0.49 ± 1.11; P < 0.0001), with a 
similar trend (−0.10 ± 0.94 vs. 0.21 ± 1.06; P = 0.007) for those with impaired relaxation 
(group 1). However, subjects with normal diastolic function and those with combined 
dysfunction (group 3) had similar levels of NT-proBNP (−0.10 ± 0.94 vs. –0.04 ± 1.11; 
P = 0.76). 
Figure 1  The histograms of the NT-proBNP levels (A, C) and the corresponding z-
scores (B, D) by the FLEMENGHO and EPOGH cohort 
Discussion 
Epidemiological studies performed in the general population provide an unbiased estimation 
of the prevalence and prognostic significance of health-related states or events (LVDD in our 
study). Epidemiology is highly regarded in evidence-based medicine for identifying risk 
factors for disease and determining optimal treatment approaches for clinical practice. 
Because the process of myocardial remodeling starts before the onset of symptoms, we place 
special emphasis on the detection of subclinical (asymptomatic) LV systolic and diastolic 
dysfunction and the timely identification of patients who are at risk for developing overt HF. 
Thus, the present report focused on the prevalence and comparison of echocardiographic 
criteria for LVDD between populations. Mean age of the FLEMENGHO and EPOGH 
participants was 51.1 and 44.5 years and the prevalence of LVDD was 24.7% and 20.2%. The 
age-standardized estimated were 22.4% and 25.1%, respectively. The key finding was that 
age-specific cut-off limits for the transmitral E/A ratio and the threshold for the E/e’ ratio, 
which we used for the classification of LVDD, were consistent and reproducible across two 
independently recruited population cohorts. The same also applied to the correlates of the 
E/A, e’/a’ and E/e’ ratios. These observations lend support to the clinical applicability of the 
criteria for the classification of LVDD as proposed in this report. 
The reported prevalence of LVDD depends on several factors, such as the characteristics of 
the population under study, imaging techniques, and the criteria applied to diagnose or to 
grade LVDD (Additional file 1: Table S1). Redfield [2] and Abhayaratna [3] used similar, but 
not identical pulsed wave Doppler and TDI criteria. Three studies4-6 defined LVDD 
exclusively based on transmitral E/A ratio cutoffs. Fisher [7] and Azevedo [8] applied 
different combinations of the criteria proposed by the European Working Group on Diastolic 
Heart Failure in 1998. [17] The criteria proposed in the recently published recommendations 
[18] for the evaluation of LV diastolic function by echocardiography require further testing 
for their applicability in the general population. 
In all aforementioned studies participants were randomly recruited from populations 
(Additional file 1: Table S2). Age at recruitment was more than 45 years in 3 reports [2,4,8] 
and more than 55 years in the Rotterdam Study.[5] The Augsburg study [7] encompassed an 
age range from 25 to 75 years, whereas the Canberra study [3] enrolled only elderly from 60 
to 86 years. The prevalence of hypertension and diabetes ranged from 28.2% to 75.0% and 
from 3.3% to 54.7%, respectively. The prevalence of any grade of LVDD ranged from 11.1% 
in Augsburg [7] to 34.7% (7.3%) in Canberra [3] (Additional file 1: Table S1). In our current 
study, the frequency of any grade of LVDD was 23.0%. This estimate has to be interpreted, 
keeping in mind that age averaged 48.6 years (range, 14.2–89.5 years), and the proportions of 
women and patients with hypertension or diabetes mellitus were 42.5%, 42.4% and 3.1%, 
respectively. 
Our current study showed that 3.5% and 2.8% of the FLEMENGHO and EPOGH 
participants had a low E/A ratio in the presence of an elevated E/e’ ratio. To our knowledge, 
this group of patients was not described in previous reports [2,3] with the exception of our 
previous FLEMENGHO report.[9] In the current report, we confirmed the existence of this 
type of LVDD in EPOGH participants. The underlying mechanisms require clarification. 
Parallel increases in the pressures in the LA and LV during diastole might contribute to this 
type of LVDD. 
Recent community-based studies[2,4,19,20] explored the prognostic role of classical Doppler 
indexes and the new TDI-derived parameters. In the Olmsted study[2] mild LVDD (hazard 
ratio, 8.31; P < 0.001) and moderate or severe diastolic dysfunction (10.2; P < 0.001) 
predicted all-cause mortality, while controlling for age, sex, and EF. However, in this study, 
the authors did not adjust the models for other important cardiovascular risk factors. In 1036 
participants enrolled in the Copenhagen City Heart study[19], low systolic and A’ velocities 
derived from colour Doppler imaging and averaged from 16 myocardial segments 
independently predicted total mortality.[19] The authors did not explore whether the new TDI 
indexes captured prognostic information over and beyond classical Doppler measurements of 
diastolic function as it was shown in previous studies.[4,20] For instance, In the 
Cardiovascular Health Study,[20] the adjusted risk of development of overt HF was highest at 
the extremes of the distribution of the transmitral E/A ratio. In the Strong Heart Study,[4] all-
cause and cardiac mortality had a U-shaped relation with the E/A ratio. 
In the absence of an outcome-driven age-specific diagnostic reference frame, averaging the 
2.5 and 97.5 percentiles for the E/A ratio in subjects free from cardiovascular diseases 
included in the FLEMENGHO and EPOGH cohorts, and rounding the resulting boundaries to 
the closest integer value, produced working definitions of normal LV diastolic function, 
which can be easily remembered. Following this approach, absolute values for the normal 
lower limit of the E/A ratio, would be higher than 1.2, 1.0, 0.9, 0.8, and 0.7 in subjects aged 
<30, 30–39, 40–49, 50–59, and >60 years, respectively. The lower boundaries of the age-
specific thresholds for the E/A ratio decreased approximately by 0.10 per decade of age. In 
the FLEMENGHO and EPOGH studies, the 97.5th percentiles of E/e’ ratio in the reference 
groups were 8.6 and 8.5, respectively. These findings are in line with the data reported from 
invasive studies, that an E/e’ ratio of less than 8 accurately predicts normal LV filling 
pressure.[17,21] 
Because NT-proBNP values vary with the degree of LVDD,23 we also compared the levels of 
NT-proBNP among the LVDD groups. In line with our previously published FLEMENGHO 
findings,[9] we observed higher levels in subjects with impaired relaxation pattern (group 1) 
and in subjects with elevated LV filling pressure (group 2). However, in subjects who had an 
elevated E/e’ ratio and an abnormally low age-specific E/A (group 3), the NT-proBNP levels 
were not different from those in subjects with normal LV function. 
Our study has to be interpreted within the context of its potential limitations and strengths. 
First, the Doppler blood flow measurements and the TDI velocities are prone to measurement 
error. In the present study, one experienced observer in each center recorded all Doppler 
images using a common highly standardized imaging protocol.[9] Furthermore, all digitally 
stored images were centrally post-processed by one observer. Second, because NT-proBNP 
was measured by different methods in FLEMENGHO and EPOGH, we reported z-scores 
instead of the measured values of NT-proBNP. However, within cohorts the associations 
between the classification of LVDD and circulating NT-proBNP levels were consistent. 
Third, the patterns of transmitral flow and mitral annulus velocities depend to some extent on 
the compliance and contractile function of the left atrium. Thus, the evaluation of diastolic 
function using the proposed cut-offs might not be applicable to patients with sustained atrial 
fibrillation. Fourth, in continuous analyses, the correlates of LVDD in two cohorts were the 
same and in line with previous reports.[3-5] This observation might be considered as a 
validation of our current results. 
Conclusions 
In conclusion, LVDD has a prevalence of over 20% in European populations. To classify 
different grades of LVDD, we applied age-specific diagnostic thresholds based on a 
combination of Doppler velocities ratios derived from transmitral blood flow and mitral 
annular movement. We demonstrated that these thresholds were consistent and reproducible 
across population cohorts. This diagnostic classification needs validation in prospective 
studies in terms of progression of disease and as predictor of cardiovascular complications. 
Data collection to meet these goals is currently in progress in the FLEMENGHO and EPOGH 
cohorts. 
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